The study by the Genekor Scientific Team, titled "RediScore: Prospective Validation of a Pipeline for Homologous Recombination Deficiency Analysis," was published in Oncology Letters
read moreThe prime DX new technology for tumor molecular profiling is compatible with both FFPE and PLASMA.
read moreWe are proud to be part of the Baltic Congress of Oncologists and Surgeons 2023 Sept. 7 - Sept. 9.
Our booth is no 6.
Feel free to visit us!
read more
The study by the Genekor Scientific Team on "The evolution of comprehensive genetic analysis in neurology: Implications for precision medicine" was published in the Journal of the Neurological Sciences.
read moreMolecular Prognosis of Recurrence & Prediction of Chemotherapy Benefit in Colon & Rectal Cancer.
read more
The study by the Genekor Scientific Team on "Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer" was presented at the San Antonio Breast Cancer Symposium 2022 in the form of a Poster.
read moreThrough a two-year program, patients with suspected symptoms from Greece, Romania, Poland, the Czech Republic, Hungary, Ukraine and Israel gain free access to genetic testing with the advanced NGS (New Generation Sequencing) method, which ensures fast and reliable diagnosis of rare diseases.
read more
Another important study by the Genekor Scientific Team on “Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers” was presented by Dr. Floros Ir. Theofanis (Oncologist Pathologist, Military Doctor P.N. - Director, 5th Oncology Clinic of Metropolitan General Hospital) at ESMO CONGRESS 2022 in the form of a Poster.
read more
